AstraZeneca Faces Securities Fraud Investigation Following Failed Clinical Trial
Pomerantz Law Firm is investigating AstraZeneca PLC (NYSE: AZN) for potential securities fraud or other unlawful business practices. The investigation follows the company's July 9, 2026 announcement that its late-stage Phase-3 CARDIO-TTransform trial of Wainua—an amyloid cardiomyopathy treatment developed with Ionis Pharmaceuticals—did not meet its primary endpoint. The news caused AstraZeneca’s American Depositary Shares (ADS) to drop $10.79, or 5.7%, closing at $187.49 per ADS on July 9, 2026. The firm is seeking investors who may wish to join a potential class action lawsuit. Pomerantz LLP has offices in multiple global locations and specializes in corporate litigation, including securities fraud cases.
Tickers: $AZN
Topics: class action clinical trial failure investor protection